These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 30723115)

  • 1. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
    Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
    Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
    Llopiz D; Ruiz M; Silva L; Repáraz D; Aparicio B; Egea J; Lasarte JJ; Redin E; Calvo A; Angel M; Berzofsky JA; Stroncek D; Sarobe P
    Cancer Lett; 2021 Feb; 499():279-289. PubMed ID: 33232788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
    Inoue S; Yamane Y; Tsukamoto S; Murai N; Azuma H; Nagao S; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
    Bioorg Med Chem Lett; 2021 Sep; 48():128247. PubMed ID: 34271070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
    Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
    Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
    McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
    Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
    Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
    Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

  • 8. AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity.
    Terry S; Abdou A; Engelsen AST; Buart S; Dessen P; Corgnac S; Collares D; Meurice G; Gausdal G; Baud V; Saintigny P; Lorens JB; Thiery JP; Mami-Chouaib F; Chouaib S
    Cancer Immunol Res; 2019 Nov; 7(11):1789-1802. PubMed ID: 31488404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
    Paolino M; Choidas A; Wallner S; Pranjic B; Uribesalgo I; Loeser S; Jamieson AM; Langdon WY; Ikeda F; Fededa JP; Cronin SJ; Nitsch R; Schultz-Fademrecht C; Eickhoff J; Menninger S; Unger A; Torka R; Gruber T; Hinterleitner R; Baier G; Wolf D; Ullrich A; Klebl BM; Penninger JM
    Nature; 2014 Mar; 507(7493):508-12. PubMed ID: 24553136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
    Kim NY; Lee HY; Lee C
    Int J Oncol; 2015 Jul; 47(1):353-60. PubMed ID: 25975389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer.
    Bosurgi L; Bernink JH; Delgado Cuevas V; Gagliani N; Joannas L; Schmid ET; Booth CJ; Ghosh S; Rothlin CV
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):13091-6. PubMed ID: 23878224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
    Wang HQ; Mulford IJ; Sharp F; Liang J; Kurtulus S; Trabucco G; Quinn DS; Longmire TA; Patel N; Patil R; Shirley MD; Chen Y; Wang H; Ruddy DA; Fabre C; Williams JA; Hammerman PS; Mataraza J; Platzer B; Halilovic E
    Cancer Res; 2021 Jun; 81(11):3079-3091. PubMed ID: 33504557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.
    Sinha S; Boysen J; Nelson M; Secreto C; Warner SL; Bearss DJ; Lesnick C; Shanafelt TD; Kay NE; Ghosh AK
    Clin Cancer Res; 2015 May; 21(9):2115-26. PubMed ID: 25673699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells.
    Lee YJ; Lim T; Han MS; Lee SH; Baek SH; Nan HY; Lee C
    Oncol Rep; 2017 Feb; 37(2):1219-1226. PubMed ID: 28035396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment.
    Li MC; Lai YL; Kuo PH; Reddy JS; Chen CM; Manimala J; Wang PC; Wu MS; Chang CY; Yang CM; Lin CY; Huang YC; Chiu CH; Chang L; Lin WH; Yeh TK; Yen WC; Hsieh HP
    J Med Chem; 2024 Jul; 67(13):10906-10927. PubMed ID: 38913493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Mertk Signaling Enhances Bone Healing after Tooth Extraction.
    Decker AM; Matsumoto M; Decker JT; Roh A; Inohara N; Sugai J; Martin K; Taichman R; Kaigler D; Shea LD; Núñez G
    J Dent Res; 2023 Sep; 102(10):1131-1140. PubMed ID: 37350025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH.
    Grøndal SM; Tutusaus A; Boix L; Reig M; Blø M; Hodneland L; Gausdal G; Jackson A; Garcia de Frutos P; Lorens JB; Morales A; Marí M
    Front Immunol; 2024; 15():1400553. PubMed ID: 38817615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment?
    Msaouel P; Genovese G; Gao J; Sen S; Tannir NM
    Expert Opin Ther Targets; 2021 Feb; 25(2):141-151. PubMed ID: 33356674
    [No Abstract]   [Full Text] [Related]  

  • 20. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
    Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
    Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.